Immunomedics, Inc. (IMMU) on Q2 2019 Results - Earnings Call Transcript

Immunomedics, Inc. (IMMU) Q2 2019 Earnings Conference Call August 7, 2019 5:00 PM ET

Company Participants

Chau Cheng - Senior Director, IR
Behzad Aghazadeh - Executive Chairman
Scott Canute - Executive Director
Usama Malik - CFO
Robert Iannone - Head of R&D and Chief Medical Officer

Conference Call Participants

Corinne Jenkins - Goldman Sachs
Phil Nadeau - Cowen & Company
Shanshan Xu - Berenberg Capital Markets
Chris Howerton - Jefferies
Yige Guo - Guggenheim
Matthew Harrison - Morgan Stanley

Operator

Good afternoon, ladies and gentlemen, thank you for standing by. As reminder, this call is being recorded today is Wednesday, August 7, 2019.

At this time, I would like to turn the conference over to Chau Cheng, Senior Director of Investor Relations at Immunomedics.

Chau Cheng

Thank you, Laura. Before we begin I would like to remind everyone that during this call, we will be making forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements may involve significant risks and uncertainties and therefore actual results could differ materially from those expressed or implied on this call. The factors that could cause such differences please refer to our regulatory filings with the Securities and Exchange Commission.

With us on the call today with prepared remarks are Dr. Behzad Aghazadeh, Executive Chairman; and Usama Malik, Chief Financial Officer. Also on the call for Q&A is Scott Canute, Executive Director. Following the prepared remarks, we will open the call up for questions. Thank you. Behzad?

Behzad Aghazadeh

Thank you, Chau. Good morning everyone, and thank you for joining us. First and foremost, let me begin with an update on our BLA resubmission efforts. I’m pleased to report that we remain on track to meet our guided resubmission timeline of early fourth quarter of 2019. As noted by Scott in our last earnings call, our goal